Relation between augmentation index and adiponectin during one-year metformin treatment for nonalcoholic steatohepatosis: effects beyond glucose lowering? Full Text
Cardiovascular Diabetology, 06/08/2012
Shargorodsky M et al. – Metformin treatment was associated with significant decrease in augmentation index (AI) during one year treatment in nonalcoholic fatty liver disease (NAFLD) patients. These beneficial vascular effects was associated with exposure to metformin per se as well as change in adiponectin levels suggesting that metformin may mediate its vascular effects via glicemic control–independent mechanisms.